Testing how bumetanide works in people with heart failure
Tests bumetanide, a water pill, at different doses in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
Key facts
- Where
- New Haven, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Yale UniversityNew Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT05323487
- Record updated
- 22 May 2026
- Original description
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.Read full original descriptionShow less
Mechanisms of Diuretic Resistance in Heart Failure
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
Inclusion: Clinical diagnosis of HF; No plan for titration/change of heart failure medical or device therapies during the study period; Absence of non-elective hospitalizations in the previous 3 months; At optimal volume status by symptoms, exam, and dry weight; Age > 18 years.
Exclusion: History of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive HF phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc); GFR <20 ml/min/1.73m2 using the Chronic Kidney Disease- Epidemiology (CKD-EPI)equation or use of renal replacement therapies; Hemoglobin < 8 g/dL; Use of any non-loop type diuretic in the last 14 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). Examples of non-loop diuretics include but may not be limited to acetazolamide (oral or IV, not ophthalmic), metolazone, Hydrochlorothiazide (HCTZ), chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose > 50mg day, eplerenone > 50mg/day,; Pregnant or breastfeeding; Inability to give written informed consent or comply with study protocol or follow-up visits; Chronic Urinary retention limiting ability to perform timed urine collection procedures.